Research indicates potential cure for hypertension with sustained blood pressure improvement — Evidence Review

A new study suggests that the drug baxdrostat may provide long-lasting blood pressure control and potentially cure a subset of hypertension patients even after treatment stops. Related studies generally show that most blood pressure medications require ongoing use for sustained benefit, making this possible long-term or curative effect notable (see study in the New England Journal of Medicine).

• Traditional antihypertensive drugs, including thiazides, ACE inhibitors, and beta-blockers, consistently reduce cardiovascular events and blood pressure but typically require continuous administration, with effects diminishing after cessation (1, 2, 3).
• Recent research into newer therapies, such as dual combination regimens and device-based interventions, has focused on improving efficacy, tolerability, and long-term outcomes, but none have demonstrated lasting blood pressure normalization after treatment withdrawal (5, 9, 10).
• The observed potential for baxdrostat to induce durable remission or cure in primary aldosteronism patients contrasts with the current paradigm and highlights a unique therapeutic mechanism not previously reported in large-scale antihypertensive trials (13).

Study Overview and Key Findings

Hypertension, affecting over a billion people worldwide, is commonly managed with daily medication, but cure is rare. A new study led by Prof Morris Brown at Queen Mary University of London and Prof Mason Freeman at Harvard University investigates baxdrostat, an aldosterone synthase inhibitor (ASI), for its ability to achieve lasting blood pressure control in a subset of patients with primary aldosteronism—a form of hypertension caused by benign adrenal gland tumors. The study drew attention due to some patients maintaining normal blood pressure for up to two years after discontinuing the drug, raising the possibility of a durable treatment effect or cure. The underlying mechanism is hypothesized to involve selective destruction of hormone-producing adrenal cells, though this requires further confirmation.

Property	Value
Organization	Queen Mary University of London, Harvard University
Journal Name	New England Journal of Medicine
Authors	Prof Morris Brown, Mason Freeman
Population	Patients with high blood pressure
Sample Size	14 patients
Methods	Non-randomized Controlled Trial (Non-RCT)
Outcome	Blood pressure improvement, potential cure for hypertension
Results	Some patients maintained lower blood pressure up to two years later.

Literature Review: Related Studies

To contextualize these findings, we searched the Consensus paper database, which contains over 200 million research papers, using the following queries:

1. high blood pressure drug efficacy
2. long-term blood pressure outcomes
3. new hypertension treatment patient studies

Below, we group key findings from related literature by major research themes:

Topic	Key Findings
What are the long-term effects of antihypertensive therapies?	- Most antihypertensive drugs require continuous use; blood pressure usually rises again after stopping medication (1, 2, 3, 10). - Durable long-term normalization/cure of hypertension is rare (8, 9).
How do new drug classes and mechanisms compare to traditional agents?	- New classes (aldosterone synthase inhibitors, endothelin antagonists, RNAi therapeutics) lower blood pressure effectively, but long-term remission after discontinuation is unproven (11, 13, 14). - Most new drugs are evaluated for efficacy and safety during active treatment, not for persistent effects post-treatment (13, 14, 15).
What are the benefits and limitations of intensive or combination therapy?	- Intensive lowering of blood pressure reduces cardiovascular risk but increases some adverse events (6, 7, 12). - Low-dose dual or triple combination therapy improves blood pressure control and tolerability over monotherapy, but ongoing therapy is needed (2, 5, 15).

What are the long-term effects of antihypertensive therapies?

The standard approach to hypertension management involves continuous medication; sustained blood pressure reduction after stopping therapy is rare. Meta-analyses and randomized trials consistently show that benefits are linked to ongoing drug use, and blood pressure typically rises again when treatment ends (1, 2, 3, 10). The possibility of a curative effect, as suggested in the baxdrostat study, represents a significant departure from established patterns.

• Meta-analyses indicate all major antihypertensive classes lower cardiovascular risk, but only while medication is continued (1, 3).
• Telemonitoring and pharmacist interventions can result in sustained blood pressure control for up to 24 months, but benefits wane after stopping active management (10).
• Catheter-based interventions like renal artery denervation can reduce blood pressure for years but do not eliminate the need for further antihypertensive strategies, and most patients do not achieve “cure” (9).
• Long-term cardiovascular risk persists in young adults with raised blood pressure, and evidence for curing hypertension is limited (8).

How do new drug classes and mechanisms compare to traditional agents?

Recent developments in antihypertensive therapy, including aldosterone synthase inhibitors (like baxdrostat), endothelin antagonists, and RNAi-based treatments, have demonstrated efficacy in lowering blood pressure in difficult-to-treat populations (11, 13, 14). However, most studies focus on short- to medium-term efficacy during active treatment; evidence for a lasting benefit after discontinuation is lacking.

• Baxdrostat significantly lowers systolic blood pressure in resistant and uncontrolled hypertension, but published trials to date have not assessed post-treatment remission (13).
• Endothelin receptor antagonists (e.g., darusentan) and RNAi agents (e.g., zilebesiran) provide additional blood pressure reductions but require repeated dosing and do not show cure-like effects (11, 14).
• New single-pill combination therapies efficiently reduce blood pressure, yet their effect is dependent on continued administration (15).
• The curative potential observed in the recent baxdrostat study is unique and not reported for other new classes (11, 13, 14).

What are the benefits and limitations of intensive or combination therapy?

Trials of intensive blood pressure lowering and combination drug regimens consistently show improved blood pressure control and reduced cardiovascular risk compared to standard monotherapy (2, 5, 6, 7, 12, 15). Nevertheless, these approaches require ongoing therapy, and intensive regimens may increase adverse events such as hypotension or renal issues.

• Intensive blood pressure targets (<120 mm Hg) reduce major cardiovascular events, but with increased adverse effects (6, 7, 12).
• Low-dose combination therapies (dual or triple) achieve greater blood pressure reductions and are often better tolerated than higher-dose monotherapy (2, 5, 15).
• Mortality and morbidity reductions are proportional to the degree of blood pressure reduction, not necessarily the specific drug used (1, 3, 4).
• No combination or intensive therapy to date has demonstrated sustained blood pressure normalization after treatment withdrawal (2, 5, 6).

Future Research Questions

Given the small sample size and non-randomized design of the new baxdrostat study, along with its potentially paradigm-shifting findings, several important questions remain. Further investigation is required to confirm these results, elucidate mechanisms, and explore broader applicability across hypertensive populations.

Research Question	Relevance
Does baxdrostat induce long-term remission or cure in a large cohort of hypertension patients?	Large-scale randomized trials are needed to determine whether the remission/cure effect persists in a broader population and is not limited to a select few (13).
What is the cellular mechanism by which baxdrostat might eliminate aldosterone-producing cells?	Understanding the drug's mechanism could optimize treatment and identify other potential targets for curative hypertension therapy (13).
Can other aldosterone synthase inhibitors or novel agents produce similar long-term effects in hypertension?	Investigating whether this effect is unique to baxdrostat or generalizable to similar drugs could broaden treatment options (11, 13, 14).
What patient characteristics predict long-term remission after treatment with baxdrostat?	Identifying predictors of response may enable personalized treatment strategies and optimize patient selection (13).
Are there long-term adverse effects of baxdrostat after treatment discontinuation?	Assessing safety beyond the treatment period is essential for evaluating the risk-benefit ratio of attempting cure (13).